Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
about
Interferon Regulatory Factor 1 (IRF-1) induces p21(WAF1/CIP1) dependent cell cycle arrest and p21(WAF1/CIP1) independent modulation of survivin in cancer cellsMicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.Ultrasound-targeted microbubble destruction (UTMD) assisted delivery of shRNA against PHD2 into H9C2 cells.Study of the UTMD-based delivery system to induce cervical cancer cell apoptosis and inhibit proliferation with shRNA targeting Survivin.Targeted gene delivery in tumor xenografts by the combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit survivin gene expression and induce apoptosisIdentification of biomarkers in ductal carcinoma in situ of the breast with microinvasion.Complex sense-antisense architecture of TNFAIP1/POLDIP2 on 17q11.2 represents a novel transcriptional structural-functional gene module involved in breast cancer progressionIAP regulation of metastasis.1,1-Bis(3'-indolyl)-1-(p-bromophenyl)methane and related compounds repress survivin and decrease gamma-radiation-induced survivin in colon and pancreatic cancer cellsValidation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancerSurvivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity.CDK4 inhibition and doxorubicin mediate breast cancer cell apoptosis through Smad3 and survivin.Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma.Role of traditional and new biomarkers in breast carcinogenesis.The role of survivin in diagnosis, prognosis and treatment of breast cancer.Soluble-E-cadherin activates HER and IAP family members in HER2+ and TNBC human breast cancers.Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers.Long-term maintenance of prognostic value of survivin and its relationship with p53 in T4 breast cancer patientsExpression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance.Daxx represses RelB target promoters via DNA methyltransferase recruitment and DNA hypermethylationA novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancerTargeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.The multifaceted activities of AMPK in tumor progression--why the "one size fits all" definition does not fit at all?Chimeric nucleolin aptamer with survivin DNAzyme for cancer cell targeted delivery.Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.Rapamycin potentiates cytotoxicity by docetaxel possibly through downregulation of Survivin in lung cancer cells.Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy.Survivin expression is an independent poor prognostic marker in lung adenocarcinoma but not in squamous cell carcinoma.BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.Evaluation of survivin immunoexpression in the differentiation of high- and low-grade breast ductal carcinoma in situ.
P2860
Q24300739-B5EAF994-D8F9-4C80-B01C-336B90B09476Q30010065-CC44D160-729E-4244-BC92-BEC664958B3DQ30404582-FCAEAFF9-54DD-4FFB-BA98-4171B105AB7AQ30457441-48BDA76C-A7EC-47B0-9101-34EFE0ABD3D7Q30478078-21A2D69A-7C15-4D69-9D15-ADFD573D4278Q33374153-EF0EC585-B6ED-471D-BE65-471F313E30FCQ33531529-6E3CCC6E-37DE-40E8-9CFB-BD6D4201F71BQ33638504-FC323DAB-A33F-4D81-B186-D0536CF3BEA0Q33748743-D7B6AF0C-DBE0-4BEC-884B-3602BA95D082Q33752148-BC496E6E-825A-4900-9398-9A7117E453C6Q33827053-802C01A9-F438-4FDF-8417-24DF1B809BC1Q33914076-DEC7744E-3889-4DB3-8FEA-71480E6B52ECQ34036076-2045AD38-7034-4E90-B467-A1F3D680020AQ34760593-EB93C5B0-B381-4AA1-B178-2D7D910998D7Q35078238-ABD6729A-9F88-468B-B4C0-B79AEC20CC0FQ35572905-1EBFBD71-9776-46D3-B226-4E0E7915F986Q35667653-C10963EE-C9E2-45A2-9759-F30AE511CA03Q35770840-35514073-5A1A-41B7-B6C7-F320CA54D23DQ36107033-7CC6A6A3-6FA1-40CA-BE70-1E31A17CBA33Q36375382-AA2E30DF-A888-4E74-83FF-5027901DC19CQ36464535-2210BDAA-1FBD-494D-AEDA-5FF4E43D22C1Q36585524-043F3E43-E8FD-4843-925F-95CE60260613Q36800387-014334D0-A5FF-42D9-9008-C2B66F1850D8Q37222549-40C5A6F3-BD01-4113-997F-C1493B0A22A3Q37277197-F251F424-6CA9-4B67-8C72-4AE25D28D525Q38165133-1E539772-3CF1-4A15-A663-AEA0E8751ACDQ38300295-08F30D57-DCCF-474E-8CEE-856786889AE6Q38833708-BBDBE974-1FE7-424B-BC88-2083F0094FEEQ39578075-DFC22563-AB60-47BA-A504-0AFA4680DB46Q42949488-11C50A57-54B9-44D7-A4A8-F4A4D347F2C7Q45139318-2D5F4186-8E0F-42F6-9B98-36A1A2819971Q48371625-5AA1C7A5-AD10-43B0-BCCB-D7AC283A0DB1Q53013674-D962C9CA-ECB5-4D27-A2E4-BCFAB52E33D8Q55253587-825433F3-B947-480A-AFA8-DA731FEA435E
P2860
Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Survivin is an independent pre ...... nostic breast cancer patients.
@ast
Survivin is an independent pre ...... nostic breast cancer patients.
@en
type
label
Survivin is an independent pre ...... nostic breast cancer patients.
@ast
Survivin is an independent pre ...... nostic breast cancer patients.
@en
prefLabel
Survivin is an independent pre ...... nostic breast cancer patients.
@ast
Survivin is an independent pre ...... nostic breast cancer patients.
@en
P2093
P2860
P356
P1476
Survivin is an independent pre ...... nostic breast cancer patients.
@en
P2093
A R Hinnis
J C A Luckett
R A Walker
P2860
P2888
P304
P356
10.1038/SJ.BJC.6603616
P407
P577
2007-02-06T00:00:00Z